Veracyte, Inc.

Veracyte's 36.4 P/E ratio stands at a significant premium to typical healthcare services peers, yet the stock sits comfortably below its 52-week high with an RSI of 66.5—approaching overbought territory but not yet extreme. The 9.57% short interest is moderate, suggesting some skepticism about valuation justification. At $3.2B market cap, the company commands a premium multiple that implies sustained growth expectations; any slowdown in revenue or profitability could trigger multiple compression. The divergence between elevated valuation and below-peak price suggests the market may be pricing in near-term challenges while retaining conviction in longer-term potential, creating a setup more suited to patient participants rather than momentum traders.